Adenovirus Vectors: Excellent Tools for Vaccine Development

키워드

참고문헌 (56)

1. Farina SF, "Replicationdefective vector based on a chimpanzee adenovirus", J Virol, 75, pp.11603~11613 (2001)
2. Afkhami S, "Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens", Mol Ther Methods Clin Dev, 3, pp.16030~ (2016)
3. Lasaro MO, "New insights on adenovirus as vaccine vectors", Mol Ther, 17, pp.1333~1339 (2009)
4. Majhen D, "Adenovirus-based vaccines for fighting infectious diseases and cancer : progress in the field", Hum Gene Ther, 25, pp.301~317 (2014)
5. Bolinger B, "Adenoviral vector vaccination induces a conserved program of CD8(+)T cell memory differentiation in mouse and man", Cell Reports, 13, pp.1578~1588 (2015)
6. Bett AJ, "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3", Proc Natl Acad Sci U S A, 91, pp.8802~8806 (1994)
7. Kovesdi I, "Adenoviral producer cells", Viruses, 2, pp.1681~1703 (2010)
8. Wang Q, "Second-generation adenovirus vectors", Nat Med, 2, pp.714~716 (1996)
9. Kochanek S, "A new adenoviral vector : Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase", Proc Natl Acad Sci U S A, 93, pp.5731~5736 (1996)
10. Parks RJ, "A helper-dependent adenovirus vector system : removal of helper virus by Cre-mediated excision of the viral packaging signal", Proc Natl Acad Sci U S A, 93, pp.13565~13570 (1996)
11. Tamanini A, "Interaction of adenovirus type 5 fiber with the coxsackievirus and adenovirus receptor activates inflammatory response in human respiratory cells", J Virol, 80, pp.11241~11254 (2006)
12. Liu Q, "Molecular basis of the inflammatory response to adenovirus vectors", Gene Ther, 10, pp.935~940 (2003)
13. Tatsis N, "Adenoviruses as vaccine vectors", Mol Ther, 10, pp.616~629 (2004)
14. Medzhitov R, "Innate immune recognition : mechanisms and pathways", Immunol Rev, 173, pp.89~97 (2000)
15. Napier RJ, "The role of mucosal associated invariant T cells in antimicrobial immunity", Front Immunol, 6, pp.344~ (2015)
16. Provine NM, "Activation of mait cells plays a critical role in viral vector vaccine immunogenicity", bioRxiv doi: 10.1101, 2019
17. Yao Y, "Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity", Cell, 175, pp.1634.e17~1650.e17 (2018)
18. Tatsis N, "Adenoviral vectors persist in vivo and maintain activated CD8+ T cells : implications for their use as vaccines", Blood, 110, pp.1916~1923 (2007)
19. Santra S, "Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates", J Virol, 79, pp.6516~6522 (2005)
20. Li JX, "Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China : final report of a randomised, double-blind, placebo-controlled, phase 1 trial", Lancet Glob Health, 5, pp.e324~e334 (2017)
21. Yang TC, "The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity", J Immunol, 176, pp.200~210 (2006)
22. Lasaro MO, "Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques", Mol Ther, 19, pp.417~426 (2011)
23. Mueller SN, "Memory T cell subsets, migration patterns, and tissue residence", Annu Rev Immunol, 31, pp.137~161 (2013)
24. Haddadi S, "Mucosal-pull induction of lung-resident memory CD8 T cells in parenteral tb vaccine-primed hosts requires cognate antigens and CD4 T cells", Front Immunol, 10, pp.2075~ (2019)
25. Jeyanathan M, "New tuberculosis vaccine strategies : Taking aim at unnatural immunity", Trends Immunol, 39, pp.419~433 (2018)
26. Turner DL, "Lung niches for the generation and maintenance of tissue-resident memory T cells", Mucosal Immunol, 7, pp.501~510 (2014)
27. Uddback IE, "Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus", Sci Rep, 6, pp.20137~ (2016)
28. Kim MH, "Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus", Antiviral Res, 163, pp.19~28 (2019)
29. Uddbäck I, "Long-term maintenance of lung resident memory T cells is mediated by persistent antigen", Mucosal Immunol, 14, pp.92~99 (2021)
30. Bolinger B, "A new model for CD8+ T cell memory inflation based upon a recombinant adenoviral vector", J Immunol, 190, pp.4162~4174 (2013)
31. Klenerman P, "The(gradual)rise of memory inflation", Immunol Rev, 283, pp.99~112 (2018)
32. Snyder CM, "Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells", Immunity, 29, pp.650~659 (2008)
33. Lee LN, "Adenoviral vaccine induction of CD8+ T cell memory inflation : impact of co-infection and infection order", PLoS Pathog, 13, pp.e1006782~ (2017)
34. Jeyanathan M, "Immunological considerations for COVID-19 vaccine strategies", Nat Rev Immunol, 20, pp.615~632 (2020)
35. Zhu FC, "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older : a randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 396, pp.479~488 (2020)
36. Zhu FC, "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine : a doseescalation, open-label, non-randomised, first-in-human trial", Lancet, 395, pp.1845~1854 (2020)
37. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
38. Ramasamy MN, "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2021, pp.396, 1979~1993
39. Mercado NB, "Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques", Nature, 586, pp.583~588 (2020)
40. Coughlan L, "Adenoviral vectors as novel vaccines for influenza", J Pharm Pharmacol, 67, pp.382~399 (2015)
41. Sayedahmed EE, "Adenoviral vector-based vaccine platforms for developing the next generation of influenza vaccines", Vaccines(Basel), 8, pp.574~ (2020)
42. Shiver JW, "Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity", Nature, 415, pp.331~335 (2002)
43. Buchbinder SP, "Efficacy assessment of a cell-mediated immunity HIV-1 vaccine(the Step Study) : a doubleblind, randomised, placebo-controlled, test-of-concept trial", Lancet, 372, pp.1881~1893 (2008)
44. McElrath MJ, "HIV-1 vaccine-induced immunity in the test-of-concept Step Study : a case-cohort analysis", Lancet, 372, pp.1894~1905 (2008)
45. Barouch DH, "Novel adenovirus vector-based vaccines for HIV-1", Curr Opin HIV AIDS, 5, pp.386~390 (2010)
46. Baden LR, "Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention : a randomized trial", Ann Intern Med, 164, pp.313~322 (2016)
47. Wohlfart C, "Neutralization of adenoviruses : kinetics, stoichiometry, and mechanisms", J Virol, 62, pp.2321~2328 (1988)
48. Hong SS, "Identification of adenovirus(ad)penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad(addl1520)for treatment of liver tumors", J Virol, 77, pp.10366~10375 (2003)
49. Olive M, "The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope", Hum Gene Ther, 13, pp.1167~1178 (2002)
50. Roberts DM, "Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity", Nature, 441, pp.239~243 (2006)
51. O'Riordan CR, "PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo", Hum Gene Ther, 10, pp.1349~1358 (1999)
52. Xiang ZQ, "Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier", J Virol, 77, pp.10780~10789 (2003)
53. Croyle MA, "Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice", PLoS One, 3, pp.e3548~ (2008)
54. Yu JR, "Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection", J Virol, 82, pp.2350~2357 (2008)
55. Geisbert TW, "Recombinant adenovirus serotype 26(Ad26)and Ad35 vaccine vectors bypass immunity to Ad5and protect nonhuman primates against ebolavirus challenge", J Virol, 85, pp.4222~4233 (2011)
56. Xiang Z, "Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product", J Virol, 76, pp.2667~2675 (2002)

관련 논문AI추천